Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib

NCT01189435 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Lack of accrual

Conditions

Lung Cancer

Interventions

DRUG: erlotinib

Sponsor

Memorial Sloan Kettering Cancer Center